Develops antibody treatments for people with immune-mediated inflammatory diseases, including hidradenitis suppurativa.
10-K for FY2025, filed Mar 23, 2026
Historically, wholesale distributors bought prescription drugs, with sales counted when the product reached them. Avalo does not expect gross product sales until possible commercialization of its pipeline candidates.
10-K for FY2025, filed Mar 23, 2026The Company historically generated its revenue from sales of its prescription drug to its customers. The license and supply agreement for…View ↗
$59K
10-K for FY2025, filed Mar 23, 2026
$59K ↗
Avalo sold Millipred in the United States primarily through wholesale distributors.
10-K for FY2025, filed Mar 23, 2026The Company’s license and supply agreement for Millipred®, an oral prednisolone indicated across a wide variety of inflammatory conditions…View ↗
No. It lost $78.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$18.9MView ↗
Shrinking. Revenue fell 99% in 4 years, from $5.4M in FY2021 to $59K in FY2025, about 68% a year.
Treatment focus
The older report centered its pipeline on the LIGHT-signaling network; the latest report describes treatments for immune-mediated inflammatory diseases and identifies abdakibart for hidradenitis suppurativa as its main candidate.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 23, 2026Avalo Therapeutics, Inc. (the “Company”, “Avalo” or “we”) is a clinical stage biotechnology company focused on the treatment of immune…View ↗
We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory…View ↗
Asthma program
The older report said Avalo was developing an antibody for non-eosinophilic asthma; the latest report lists its LIGHT antibody among legacy programs it is not currently pursuing.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 23, 2026Avalo is currently developing AVTX-002 for the treatment of non-eosinophilic asthma (“NEA”). Our Phase 2 PEAK Trial (A Phase 2, Randomized…View ↗
Competes with Novartis, GenSci, Sunshine Guojian, TavoTek, AbbVie, UCB, Moonlake Immunotherapies, Incyte, Lilly, Merck, Pfizer, Sanofi, and Takeda
10-K for FY2025, filed Mar 23, 2026As of the date of this report, and to our knowledge, there are two companies with approved anti-IL-1β antibodies (Novartis AG or “Novartis”…View ↗
Loading...